298 related articles for article (PubMed ID: 28670693)
21. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
22. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
23. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.
Sanz-Rodríguez F; Hidalgo A; Teixidó J
Blood; 2001 Jan; 97(2):346-51. PubMed ID: 11154207
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
Weisberg E; Azab AK; Manley PW; Kung AL; Christie AL; Bronson R; Ghobrial IM; Griffin JD
Leukemia; 2012 May; 26(5):985-90. PubMed ID: 22182920
[TBL] [Abstract][Full Text] [Related]
25. CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment.
Han Y; Wu C; Wang J; Liu N
Tumour Biol; 2017 May; 39(5):1010428317701631. PubMed ID: 28468584
[TBL] [Abstract][Full Text] [Related]
26. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Udi J; Schüler J; Wider D; Ihorst G; Catusse J; Waldschmidt J; Schnerch D; Follo M; Wäsch R; Engelhardt M
Br J Haematol; 2013 Apr; 161(1):104-16. PubMed ID: 23384035
[TBL] [Abstract][Full Text] [Related]
27. CXCR7 Mediates Neural Progenitor Cells Migration to CXCL12 Independent of CXCR4.
Chen Q; Zhang M; Li Y; Xu D; Wang Y; Song A; Zhu B; Huang Y; Zheng JC
Stem Cells; 2015 Aug; 33(8):2574-85. PubMed ID: 25833331
[TBL] [Abstract][Full Text] [Related]
28. The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.
Beider K; Rosenberg E; Bitner H; Shimoni A; Leiba M; Koren-Michowitz M; Ribakovsky E; Klein S; Olam D; Weiss L; Wald H; Abraham M; Galun E; Peled A; Nagler A
Clin Cancer Res; 2017 Apr; 23(7):1733-1747. PubMed ID: 27697999
[No Abstract] [Full Text] [Related]
29. CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells.
Tarnowski M; Liu R; Wysoczynski M; Ratajczak J; Kucia M; Ratajczak MZ
Eur J Haematol; 2010 Dec; 85(6):472-83. PubMed ID: 20887389
[TBL] [Abstract][Full Text] [Related]
30. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
Wu W; Qian L; Chen X; Ding B
Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
[TBL] [Abstract][Full Text] [Related]
32. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
[TBL] [Abstract][Full Text] [Related]
33. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis.
Badr G; Lefevre EA; Mohany M
PLoS One; 2011; 6(9):e23741. PubMed ID: 21912642
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway.
Huang J; Huang LQ; He HS; Yan J; Huang C; Wang R; Guan Y; Huang DP
Life Sci; 2020 Sep; 257():118088. PubMed ID: 32663573
[TBL] [Abstract][Full Text] [Related]
35. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.
Mirandola L; Apicella L; Colombo M; Yu Y; Berta DG; Platonova N; Lazzari E; Lancellotti M; Bulfamante G; Cobos E; Chiriva-Internati M; Chiaramonte R
Leukemia; 2013 Jul; 27(7):1558-66. PubMed ID: 23354012
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
[TBL] [Abstract][Full Text] [Related]
37. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
38. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Duda DG; Kozin SV; Kirkpatrick ND; Xu L; Fukumura D; Jain RK
Clin Cancer Res; 2011 Apr; 17(8):2074-80. PubMed ID: 21349998
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
Abdi J; Mutis T; Garssen J; Redegeld FA
PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
[TBL] [Abstract][Full Text] [Related]
40. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G
Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
